With an ever-increasing emphasis on minimising drug candidate attrition, scientists are focusing on target safety at earlier points in the research process. In this exclusive interview, Drug Target Review spoke with Dr Gordon Baxter, Chief Scientific Officer of Instem, to learn how target safety assessments can enable researchers to quickly identify and assess unintended adverse consequences of potential treatments before expensive investment is made.

Discover all the fantastic content we have for you on-demand; covering all aspects of drug discovery and development, our webinars are recorded live but are available to watch at your convenience.

Researchers discover a new precision strategy to hinder the infection of the coronavirus, leading to the filing of a new drug patent.

Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.

A new study prevented the growth of metastatic tumours in mice by forcing cancer cells into a dormant state, pointing to novel treatments.